Dr. Beth Seidenberg focuses on life science investing in digital health and biotech and works with entrepreneurs to develop companies with breakthrough technology for treating patients and improving the delivery of healthcare. Since joining Kleiner Perkins in 2005, Beth has incubated five companies and was the founding CEO of two. She serves on the board of directors of 3-V Biosciences, ARMO Biosciences, Cell Design Labs, FLX Bio, Hixme, Kinsa, Progyny, Atara Bio (ATRA), Epizyme (EPZM), Tesaro (TSRO). Beth grew up in New York and received her B.S. degree from Barnard College and her M.D. from the University of Miami. She completed her post-graduate training at Johns Hopkins University, George Washington University and the National Institutes of Health.
